Your browser doesn't support javascript.
Evaluation of commercial Anti-SARS-CoV-2 neutralizing antibody assays in seropositive subjects.
Saker, Kahina; Pozzetto, Bruno; Escuret, Vanessa; Pitiot, Virginie; Massardier-Pilonchéry, Amélie; Mokdad, Bouchra; Langlois-Jacques, Carole; Rabilloud, Muriel; Alfaiate, Dulce; Guibert, Nicolas; Fassier, Jean-Baptiste; Bal, Antonin; Trouillet-Assant, Sophie; Trabaud, Mary-Anne.
  • Saker K; Laboratoire de Virologie, Institut des Agents Infectieux, Laboratoire associé au Centre National de Référence des virus des infections respiratoires, Hospices Civils de Lyon, IAI, Centre de Biologie Nord, Groupement Hospitalier Nord, F-69317, Lyon Cedex 04, France. Electronic address: kahina.saker@c
  • Pozzetto B; CIRI- International Center of Research in Infectiology, INSERM U1111, CNRS UMR5308, ENS Lyon, Claude Bernard Lyon 1 University, F-69008, Lyon, France.
  • Escuret V; Laboratoire de Virologie, Institut des Agents Infectieux, Laboratoire associé au Centre National de Référence des virus des infections respiratoires, Hospices Civils de Lyon, IAI, Centre de Biologie Nord, Groupement Hospitalier Nord, F-69317, Lyon Cedex 04, France; CIRI- International Center of Rese
  • Pitiot V; Occupational Health and Medicine Department, Hospices Civils de Lyon, Lyon, France.
  • Massardier-Pilonchéry A; Occupational Health and Medicine Department, Hospices Civils de Lyon, Lyon, France.
  • Mokdad B; Laboratoire de Virologie, Institut des Agents Infectieux, Laboratoire associé au Centre National de Référence des virus des infections respiratoires, Hospices Civils de Lyon, IAI, Centre de Biologie Nord, Groupement Hospitalier Nord, F-69317, Lyon Cedex 04, France.
  • Langlois-Jacques C; CNRS, UMR 5558, University of Lyon, Laboratoire de Biométrie et Biologie Evolutive, Equipe Biostatistique-Santé, F-69100, Villeurbanne, France.
  • Rabilloud M; CNRS, UMR 5558, University of Lyon, Laboratoire de Biométrie et Biologie Evolutive, Equipe Biostatistique-Santé, F-69100, Villeurbanne, France.
  • Alfaiate D; Occupational Health and Medicine Department, Hospices Civils de Lyon, Lyon, France.
  • Guibert N; Occupational Health and Medicine Department, Hospices Civils de Lyon, Lyon, France.
  • Fassier JB; Occupational Health and Medicine Department, Hospices Civils de Lyon, Lyon, France.
  • Bal A; Laboratoire de Virologie, Institut des Agents Infectieux, Laboratoire associé au Centre National de Référence des virus des infections respiratoires, Hospices Civils de Lyon, IAI, Centre de Biologie Nord, Groupement Hospitalier Nord, F-69317, Lyon Cedex 04, France.
  • Trouillet-Assant S; Laboratoire de Virologie, Institut des Agents Infectieux, Laboratoire associé au Centre National de Référence des virus des infections respiratoires, Hospices Civils de Lyon, IAI, Centre de Biologie Nord, Groupement Hospitalier Nord, F-69317, Lyon Cedex 04, France; CIRI- International Center of Rese
  • Trabaud MA; Laboratoire de Virologie, Institut des Agents Infectieux, Laboratoire associé au Centre National de Référence des virus des infections respiratoires, Hospices Civils de Lyon, IAI, Centre de Biologie Nord, Groupement Hospitalier Nord, F-69317, Lyon Cedex 04, France.
J Clin Virol ; 152: 105169, 2022 07.
Article in English | MEDLINE | ID: covidwho-1804471
ABSTRACT
The virus neutralization test (VNT) is the reference for the assessment of the functional ability of neutralizing antibodies (NAb) to block SARS-CoV-2 entry into cells. New competitive immunoassays measuring antibodies preventing interaction between the spike protein and its cellular receptor are proposed as surrogate VNT (sVNT). We tested three commercial sVNT (a qualitative immunochromatographic test and two quantitative immunoassays named YHLO and TECO) together with a conventional anti-spike IgG assay (bioMérieux) in comparison with an in-house plaque reduction neutralization test (PRNT50) using the original 19A strain and different variants of concern (VOC), on a panel of 306 sera from naturally-infected or vaccinated patients. The qualitative test was rapidly discarded because of poor sensitivity and specificity. Areas under the curve of YHLO and TECO assays were, respectively, 85.83 and 84.07 (p-value >0.05) using a positivity threshold of 20 for PRNT50, and 95.63 and 90.35 (p-value =0.02) using a threshold of 80. However, the performances of YHLO and bioMérieux were very close for both thresholds, demonstrating the absence of added value of sVNT compared to a conventional assay for the evaluation of the presence of NAb in seropositive subjects. In addition, the PRNT50 assay showed a reduction of NAb titers towards different VOC in comparison to the 19A strain that could not be appreciated by the commercial tests. Despite the good correlation between the anti-spike antibody titer and the titer of NAb by PRNT50, our results highlight the difficulty to distinguish true NAb among the anti-RBD antibodies with commercial user-friendly immunoassays.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Diagnostic study / Experimental Studies / Qualitative research Topics: Vaccines / Variants Limits: Humans Language: English Journal: J Clin Virol Journal subject: Virology Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Diagnostic study / Experimental Studies / Qualitative research Topics: Vaccines / Variants Limits: Humans Language: English Journal: J Clin Virol Journal subject: Virology Year: 2022 Document Type: Article